收稿日期: 2016-04-20
网络出版日期: 2016-06-30
基金资助
国家自然科学基金资助项目(81370258); 上海市科委资助项目(13JC1401703)
Stem cells and cardiac regeneration
Received date: 2016-04-20
Online published: 2016-06-30
龚惠, 陈志丹, 邹云增 . 干细胞与心肌再生[J]. 上海大学学报(自然科学版), 2016 , 22(3) : 280 -284 . DOI: 10.3969/j.issn.1007-2861.2016.03.016
Human myocardium has poor regenerative power, and significant myocardial injury results in irreversible damage, remodeling, and dysfunction. Stem cells enable promising regenerative strategies for cardiovascular diseases. The search for suitable stem cell phenotypes that will improve myocardial regenerative ability needs better understanding of the molecular mechanisms of repair and regeneration. Previous reports have suggested that several stem phenotypes regulate myocardial regeneration in vitro and in vivo. This review describes the therapeutic potential of mesenchymal stem cell (MSC) therapy in terms of angiogenic and regenerative capacity after myocardial infarction. In addition, the effect of cardiac side population cells (CSPs) and the differentiation of induced pluripotent stem cells (iPSCs) in cardiac regeneration are discussed. The review provides recent data and helps broaden therapeutic potential and clinical impact of stem cell therapy.
[1] Colucci W S. Molecular and cellular mechanisms of myocardial failure [J]. Am J Cardiol, 1997, 80: 15L-25L.
[2] Goodell M A, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo [J]. J Exp Med, 1996, 183(4): 1797-1806.
[3] Pittenger M F, Martin B J. Mesenchymal stem cells and their potential as cardiac therapeutics[J]. Circ Res, 2004, 95(1): 9-20.
[4] Zhang S, Sun A, Xu D, et al. Impact of timing on efficacy and safety of intracoronary autologous bone marrow stem cells transplantation in acute myocardial infarction: a pooled subgroup analysis of randomized controlled trials [J]. Clin Cardiol, 2009, 32(8): 458-466.
[5] Yao K, Huang R, Sun A, et al. Repeated autologous bone marrow mononuclear cell therapy in patients with large myocardial infarction [J]. Eur J Heart Fail, 2009, 11(7): 691-698.
[6] Zhang S, Ma X, Yao K, et al. Combination of CD34-positive cell subsets with infarcted myocardium-like matrix stiffness: a potential solution to cell-based cardiac repair [J]. J Cell
Mol Med, 2014, 18(6): 1236-1238.
[7] Hu X, Xu Y, Zhong Z, et al. A large-scale investigation of hypoxia-preconditioned allogeneic mesenchymal stem cells for myocardial repair in nonhuman primates: paracrine activity without remuscularization [J]. Circ Res, 2016, 118(6): 970-983.
[8] Nagai T, Matsuura K, Komuro I. Cardiac side population cells and Sca-1-positive cells [J]. Methods Mol Biol, 2013, 1036: 63-74.
[9] Liang S X, Tan T Y, Gaudry L, et al. Differentiation and migration of Sca1+/CD31−cardiac side population cells in a murine myocardial ischemic model [J]. Int J Cardiol, 2010, 138(1):
40-49.
[10] Oyama T, Nagai T, Wada H, et al. Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo [J]. J Cell Biol, 2007, 176(3): 329-341.
[11] Mouquet F, Pfister O, Jain M, et al. Restoration of cardiac progenitor cells after myocardial infarction by self-proliferation and selective homing of bone marrow-derived stem cell[J]. Circ Res, 2005, 97(11): 1090-1092.
[12] Ma H, Gong H, Chen Z, et al. Association of Stat3 with HSF1 plays a critical role in G-CSFinduced cardio-protection against ischemia/reperfusion injury [J]. J Mol Cell Cardiol, 2012,
52(6): 1282-1290.
[13] Adachi Y, Imagawa J, Suzuki Y, et al. G-CSF treatment increases side population cell infiltration after myocardial infarction in mice [J]. J Mol Cell Cardiol, 2004, 36(5): 707-710.
[14] Gong H, Ma H, Liu M, et al. Urotensin Ⅱinhibits the proliferation but not the differentiation of cardiac side population cells [J]. Peptides, 2011, 32(5): 1035-1041.
[15] Chen Z, Xu J, Ye Y, et al. Urotensin Ⅱ inhibited the proliferation of cardiac side population cells in mice during pressure overload by JNK-LRP6 signaling [J]. J Cell Mol Med, 2014, 18(5): 852-862.
[16] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors [J]. Cell, 2006, 126(4): 663-676.
[17] Denning C, Borgdorff V, Crutchley J, et al. Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform [J]. Biochim Biophys
Acta, 2015, DOI: 10.1016/j.bbamcr.2015.10.014.
[18] Den Hartogh S C, Passier R. Concise review: fluorescent reporters in human pluripotent stem cells: contributions to cardiac differentiation and their applications in cardiac disease and toxicity [J]. Stem Cells, 2016, 34(1): 13-26.
[19] Li L, Gong H, Yu H, et al. Knockdown of nucleosome assembly protein 1-like 1 promotes dimethyl sulfoxide-induced differentiation of P19CL6 cells into cardiomyocytes [J]. J Cell
Biochem, 2012, 113(12): 3788-3796.
[20] Park Y J, Luger K. Structure and function of nucleosome assembly proteins [J]. Biochem Cell Biol, 2006, 84: 549-558.
[21] Yan Y, Yin P, Gong H, et al. Nucleosome assembly protein 1-like 1 (Nap1l1) regulates the proliferation of murine induced pluripotent stem cells [J]. Cell Physiol Biochem, 2016, 38(1): 340-350.
[22] Gong H, Yan Y, Fang B, et al. Nucleosome assembly protein 1-like 1 knockdown promotes cardiomyocytes differentiation by mesoderm induction through notch signaling in mouse induced pluripotent stem cells [J]. Stem Cells, 2014, 32(7): 1759-1773.
[23] Xue Y, Yan Y, Gong H, et al. Insulin-like growth factor binding protein 4 enhances cardiomyocyte induction in mouse induced pluripotent stem cells [J]. J Cell Biochem, 2014, 115(9): 1495-1504.
[24] Cao N, Liu Z, Chen Z, et al. Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac progenitor cells [J]. Cell Res, 2012, 22(1): 219-236.
/
| 〈 |
|
〉 |
